Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. Based in New York City and Waltham, Mass. Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics to deliver transformative medicines for patients with severe autoimmune diseases.
Since raising a $100M Series A in April 2022 co-led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company, with participation from additional investors including Wedbush Healthcare Partners and founding investors Fairmount, Tellus BioVentures, and Venrock Healthcare Capital Partners, Dianthus continues to make progress in advancing its lead monoclonal antibody, DNTH103.
On May 3rd, 2023, Dianthus announced it entered into a reverse merger transaction with Magenta Therapeutics, a publicly traded biotech company, to create a new public company with the sole focus on advancing Dianthus’ pipeline of next generation complement therapies. In support of the merger, Dianthus has secured commitments for a $70 million private investment in its common stock and pre-funded warrants from a syndicate of healthcare investors led by Fidelity Management & Research Company, Catalio Capital Management, 5AM Ventures, Avidity Partners, Wedbush Healthcare Partners and founding investors Fairmount, Tellus BioVentures and Venrock Healthcare Capital Partners, that is expected to close immediately prior to completion of the merger. With the cash expected from both companies at closing and the proceeds of the concurrent private financing, the combined company is expected to have approximately $180 million of cash or cash equivalents immediately post-closing.
Dianthus has a steady cadence of milestones with DNTH103 including top line Phase 1 data aiming to confirm potent classical pathway inhibition and favorable, extended PK expected by the end of 2023, initiation of planned Phase 2 trial in generalized Myasthenia Gravis expected in Q1 2024 followed by two additional planned Phase 2 trial initiations in other neuro indications, and planned initiation of an open label proof of efficacy trial in Cold Agglutinin Disease with patient data expected in 2H 2024.
About the Role
As Head of Investor Relations and Corporate Affairs, you will be responsible for developing and executing strategic investor relations and corporate affairs programs to communicate our scientific vision and business updates and will play a crucial role in building and maintaining strong relationships with our investors and key stakeholders.
In partnership with the CFO, you will act as the primary point of contact with the investment community. You will also work closely with other members of the executive team, such as the CEO, CMO and CSO, and own the design and development of all company internal and external communication materials to successfully tell our story and support our positioning in the market.
Ideally, you will have a scientific background and a proven track record of investor relations within the biotechnology or pharmaceutical industry including demonstrated success in raising capital.
This is an exciting opportunity to join a clinical-stage biotech company and have a significant impact on our success. We are building a team who hold our core principles at the center of our operations, with the goal to elevate the care of our patients’ lives.
- Develop and execute investor relations and corporate affairs strategies and tactics to effectively communicate our scientific vision, progress, and performance to the internal and external stakeholders.
- Build and maintain strong relationships with investors, analysts, and other internal and external stakeholders, and ensure regular communication and engagement.
- Provide strategic counsel to executive management on investor relations and corporate affairs matters, including messaging, and positioning.
- Lead the development of key communication materials, such as investor decks, press releases, earnings releases, conference call scripts, and internal presentations to support employee communications.
- Coordinate and prepare for investor events, including investor conferences and one-on-one meetings.
- Monitor and analyze market trends, peer group activities, and investor sentiment to inform investor relations strategies and tactics.
- Collaborate closely with internal teams, including finance, legal, and scientific teams, to ensure alignment and consistency in messaging internally and externally.
- Serve as a spokesperson for the company with the investment community.
- Bachelor's degree required. Degree in scientific background, MS or MBA preferred.
- Minimum of 10 years of experience in a publicly traded biotech/pharmaceutical company and/or at an investor relations firm working with biotech/pharmaceutical clients
- Strong Knowledge of industry trends
- Deep understanding of capital markets and the financial statements and valuation models used by investors and analysts.
- Well-versed in SEC and FDA regulations impacting investor and other external communications.
- Excellent written and verbal communication skills, with the ability to translate complex scientific concepts into clear and concise messaging for investors.
- High proficiency in PowerPoint/ Google Slides, Nasdaq IR Insights, BusinessWire and other relevant IT platforms
- Proven track record of success in building and maintaining strong relationships with investors and other stakeholders.
- Strong analytical and financial acumen, with the ability to analyze market trends and financial data to inform investor relations strategies and tactics.
- Experience developing and executing successful investor relations strategies and tactics.
- Excellent organizational skills and attention to detail, with the ability to manage multiple projects simultaneously.
- Ability to work collaboratively with internal teams and external partners.